MetaCap

Benitec Biopharma (BNTC) vs Greenwich LifeSciences (GLSI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Greenwich LifeSciences (GLSI) has outperformed Benitec Biopharma (BNTC) over the past year, gaining 136.2% versus a loss of 40.3%. Over five years, GLSI leads with a -41.8% price change compared with -85.7% for BNTC. Benitec Biopharma is the larger company by market cap ($285.9 million vs $282.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTC-40.31%GLSI+136.20%
+329%+136%-58%
Nov 21, 20251 yearNov 20, 2026
BNTC-85.45%GLSI-44.75%
+6%-47%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTC versus GLSI key metrics
MetricBNTCGLSI
Share price$7.92$19.25
Market cap$285.88M$282.56M
1-day change-2.76%-2.73%
YTD return-41.24%-8.38%
1-year return-40.31%+136.20%
5-year return-85.67%-41.84%
EPS (TTM)$-1.02$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-45.55M$-19.36M
52-week high$14.39$34.10
52-week low$7.72$7.78
Distance from 52-week high-45.00%-43.55%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+200.06%+198.70%
Average volume174.01K160.76K
Shares outstanding36.12M14.68M
Employees24—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GLSI has outperformed BNTC by 176.5 percentage points over the past year.

About Benitec Biopharma

BNTC stock →

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees

About Greenwich LifeSciences

GLSI stock →

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.

Health Care · Biotechnology: Pharmaceutical Preparations

BNTC vs GLSI FAQ

Which is bigger, Benitec Biopharma or Greenwich LifeSciences?

Benitec Biopharma (BNTC) is larger, with a market capitalization of $285.88M compared with $282.56M for Greenwich LifeSciences (GLSI).

Which stock has performed better over the past year, BNTC or GLSI?

GLSI returned +136.20% over the past 12 months, compared with -40.31% for BNTC (price return, excluding dividends). Past performance does not predict future results.

Are Benitec Biopharma and Greenwich LifeSciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons